Relationship between β-Secretase, Inflammation and Core Cerebrospinal Fluid Biomarkers for Alzheimer's Disease

Journal of Alzheimer's Disease

Volumn 42, Issue 1, 2014, Pages 157-167

  Alcolea, Daniel ^a,b   Carmona Iragui, María ^a,b   Suárez Calvet, Marc ^a,b   Sánchez Saudinós, M Belén ^a,b   Sala, Isabel ^a,b   Antón Aguirre, Sofía ^a,b   Blesa, Rafael ^a,b   Clarimón, Jordi ^a,b   Fortea, Juan ^a,b   Lleó, Alberto ^a,b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

Author keywords

Alzheimer's disease; amyloid protein precursor; biological markers; cerebrospinal fluid; frontotemporal dementia; inflammation; YKL 40; secretase

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BETA SECRETASE; BIOLOGICAL MARKER; CHITINASE; CHITINASE 3 LIKE 1 PROTEIN; SOLUBLE AMYLOID BETA PROTEIN PRECURSOR BETA; TAU PROTEIN; UNCLASSIFIED DRUG; ADIPOCYTOKINE; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); AMYLOID PRECURSOR PROTEIN; APP PROTEIN, HUMAN; CHI3L1 PROTEIN, HUMAN; LECTIN; MAPT PROTEIN, HUMAN; PEPTIDE FRAGMENT; SECRETASE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; COGNITIVE DEFECT; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE CLASSIFICATION; ENZYME ACTIVITY; FEMALE; FRONTAL VARIANT FRONTOTEMPORAL DEMENTIA; FRONTOTEMPORAL DEMENTIA; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MOLECULAR PATHOLOGY; NERVE CELL LESION; NERVOUS SYSTEM INFLAMMATION; PRIORITY JOURNAL; PROGRESSIVE NONFLUENT APHASIA; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN PHOSPHORYLATION; RECEIVER OPERATING CHARACTERISTIC; SEMANTIC DEMENTIA; UPREGULATION; CEREBROSPINAL FLUID; COGNITION DISORDERS; MIDDLE AGED; PHOSPHORYLATION; SENSITIVITY AND SPECIFICITY;

ADIPOKINES; AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; BIOLOGICAL MARKERS; COGNITION DISORDERS; FEMALE; FRONTOTEMPORAL DEMENTIA; HUMANS; LECTINS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PHOSPHORYLATION; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TAU PROTEINS;

EID: 84926261812     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-140240     Document Type: Article

References (57)

1. Blennow K, Hampel H (2003) CSF markers for incipient Alzheimer's disease. Lancet 2, 605-613.
2. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM- Y, Trojanowski JQ (2009) Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 65, 403-413.
3. Andreasen N, Vanmechelen E, Vanderstichele H, Davidssson P, Vanmechelen E, Davidsson P, Blennow K (2003) Cerebrospinal fluid levels of total-tau, phospho-tau and Aβ42 predicts development of Alzheimer's disease in patients with mild cognitive impairment. Acta Neurol Scand 107, 47-51.
4. Riemenschneider M, Lautenschlager N, Wagenpfeil S, Diehl J, Drzezga A, KurzA(2002) Cerebrospinal fluid tau and betaamyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment. Arch Neurol 59, 1729-1734.
5. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L (2006) Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: A follow-up study. Lancet Neurol 5, 228-234.
6. Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O (2012) Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry 69, 98-106.
7. Vos SJ B, Xiong C, Visser PJ, Jasielec MS, Hassenstab J, Grant EA, Cairns NJ, Morris JC, Holtzman DM, Fagan AM (2013) Preclinical Alzheimer's disease and its outcome: A longitudinal cohort study. Lancet Neurol 44, 1-9.
8. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH (2011) The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 263-269.
9. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, Phelps CH (2011) The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 270-279.
10. Toledo JB, Korff A, Shaw LM, Trojanowski JQ, Zhang J (2013) CSF α-synuclein improves diagnostic and prognostic performance of CSF tau and Aβ in Alzheimer's disease. Acta Neuropathol 126, 683-697.
11. Fagan AM, Perrin RJ (2012) Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer's disease. Biomark Med 6, 455-476.
12. Lleó A, Saura CA (2011) Y-secretase substrates and their implications for drug development in Alzheimer's disease. Curr Top Med Chem 11, 1513-1527.
13. Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, Luo Y, Fisher S, Fuller J, Edenson S, Lile J, Jarosinski MA, Biere AL, Curran E, Burgess T, Louis JC, Collins F, Treanor J, Rogers G, CitronM(1999) Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286, 735-741.
14. Fukumoto H, Cheung BS, Hyman BT, Irizarry MC (2002) Beta-secretase protein and activity are increased in the neocortex in Alzheimer disease. Arch Neurol 59, 1381-1389.
15. Pera M, Alcolea D, Sánchez-Valle R, Guardia-Laguarta C, Colom-Cadena M, Badiola N, Suárez-Calvet M, Lladó A, Barrera-Ocampo AA, Sepulveda-Falla D, Blesa R, Molinuevo JL, Clarimón J, Ferrer I, Gelpi E, Lleó A (2013) Distinct patterns ofAPPprocessing in theCNSin autosomal-dominant and sporadic Alzheimer disease. Acta Neuropathol 125, 201-213.
16. Li R, Lindholm K, Yang L, Yue X, Citron M, Yan R, Beach T, Sue L, Sabbagh M, Cai H, Wong P, Price D, Shen Y (2004) Amyloid beta peptide load is correlated with increased betasecretase activity in sporadic Alzheimer's disease patients. Proc Natl Acad Sci U S A 101, 3632-3637.
17. Verheijen JH, Huisman LGM, van Lent N, Neumann U, Paganetti P, Hack CE, Bouwman F, Lindeman J, Bollen ELE M, Hanemaaijer R (2006) Detection of a soluble form of BACE-1 in human cerebrospinal fluid by a sensitive activity assay. Clin Chem 52, 1168-1174.
18. Ewers M, Zhong Z, Bürger K, Wallin A, Blennow K, Teipel SJ, Shen Y, HampelH(2008) Increased CSF-BACE 1 activity is associated with ApoE-epsilon 4 genotype in subjects with mild cognitive impairment and Alzheimer's disease. Brain 131, 1252-1258.
19. Zetterberg H, Andreasson U, Hansson O, Wu G, Sankaranarayanan S, Andersson ME, Buchhave P, Londos E, Umek RM, Minthon L, Simon AJ, Blennow K (2008) Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease. Arch Neurol 65, 1102-1107.
20. Wu G, Sankaranarayanan S, Hsieh SH- K, Simon AJ, Savage MJ (2011) Decrease in brain soluble amyloid precursor protein β (sAPPβ) in Alzheimer's disease cortex. J Neurosci Res 89, 822-832.
21. Zhong Z, Ewers M, Teipel S, Bürger K, Wallin A, Blennow K, He P, McAllister C, Hampel H, Shen Y (2007) Levels of beta-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment. Arch Gen Psychiatry 64, 718-726.
22. Wu G, Sankaranarayanan S, Tugusheva K, Kahana J, Seabrook G, Shi X- P, King E, Devanarayan V, Cook JJ, Simon AJ (2008) Decrease in age-adjusted cerebrospinal fluid betasecretase activity in Alzheimer's subjects. Clin Biochem 41, 986-996.
23. Rosén C, Andreasson U, Mattsson N, Marcusson J, Minthon L, Andreasen N, Blennow K, Zetterberg H (2012) Cerebrospinal fluid profiles of amyloid β-related biomarkers in Alzheimer's disease. Neuromolecular Med 14, 65-73.
24. Perneczky R, Alexopoulos P (2013) Cerebrospinal fluid BACE1 activity and markers of amyloid precursor protein metabolism and axonal degeneration in Alzheimer's disease. Alzheimers Dement, doi: 10.1016/j.jalz.2013.09.006 [Epub ahead of print].
25. Lewczuk P, Kamrowski-Kruck H, Peters O, Heuser I, Jessen F, Popp J, Bürger K, Hampel H, Frölich L, Wolf S, Prinz B, Jahn H, Luckhaus C, Perneczky R, Hüll M, Schröder J, Kessler H, Pantel J, Gertz H- J, KlafkiH- W, Kölsch H, Reulbach U, Esselmann H, Maler JM, Bibl M, Kornhuber J, Wiltfang J (2010) Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: A multicenter study. Mol Psychiatry 15, 138-145.
26. Gabelle A, Roche S, Gény C, Bennys K, Labauge P, Tholance Y, Quadrio I, Tiers L, Gor B, Chaulet C, Vighetto A, Croisile B, Krolak-Salmon P, Touchon J, Perret-Liaudet A, Lehmann S (2010) Correlations between soluble α/β forms of amyloid precursor protein and Aβ38, 40, and 42 in human cerebrospinal fluid. Brain Res 1357, 175-183.
27. Olsson A, Höglund K, Sjögren M, Andreasen N, Minthon L, Lannfelt L, Buerger K, Möller HJ, Hampel H, Davidsson P, Blennow K (2003) Measurement of alpha- and beta-secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patients. Exp Neurol 183, 74-80.
28. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, O'Banion MK, Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, Shen Y, Streit W, Strohmeyer R, Tooyoma I, VanMuiswinkel FL, Veerhuis R, Walker D, Webster S, Wegrzyniak B, Wenk G, Wyss-Coray T (2000) Inflammation and Alzheimer's disease. Neurobiol Aging 21, 383-421.
29. Carter SF, Schöll M, Almkvist O, Wall A, Engler H, L°angström B, Nordberg A (2012) Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: A multitracer PET paradigm combining 11C-Pittsburgh compoundBand 18F-FDG. J Nucl Med 53, 37-46.
30. Johansen JS, Schultz NA, Jensen BV (2009) Plasma YKL-40: A potential new cancer biomarker? Future Oncol 5, 1065-1082.
31. Comabella M, Fernández M, Martin R, Rivera-Vallvé S, Borrás E, Chiva C, Julia E, Rovira A, Cantó E, Alvarez- Cermeño JC, Villar LM, Tintoré M, Montalban X (2010) Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis. Brain 133, 1082-1093.
32. Craig-Schapiro R, Perrin RJ, Roe CM, Xiong C, Carter D, Cairns NJ, Mintun MA, Peskind ER, Li G, Galasko DR, Clark CM, Quinn JF, D'Angelo G, Malone JP, Townsend RR, Morris JC, Fagan AM, Holtzman DM(2010) YKL-40: A novel prognostic fluid biomarker for preclinical Alzheimer's disease. Biol Psychiatry 68, 903-912.
33. Olsson B, Hertze J, Lautner R, Zetterberg H, Nägga K, Höglund K, Basun H, Annas P, Lannfelt L, Andreasen N, Minthon L, Blennow K, Hansson O (2013) Microglial markers are elevated in the prodromal phase of Alzheimer's disease and vascular dementia. J Alzheimers Dis 33, 45-53.
34. Perrin RJ, Craig-Schapiro R, Malone JP, Shah AR, Gilmore P, Davis AE, Roe CM, Peskind ER, Li G, Galasko DR, Clark CM, Quinn JF, Kaye JA, Morris JC, Holtzman DM, Townsend RR, Fagan AM (2011) Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's disease. PLoS One 6, e16032.
35. Mattsson N, Tabatabaei S, Johansson P, Hansson O, Andreasson U, M°ansson J- E, Johansson J- O, Olsson B, Wallin A, Svensson J, Blennow K, Zetterberg H (2011) Cerebrospinal fluid microglial markers in Alzheimer's disease: Elevated chitotriosidase activity but lack of diagnostic utility. Neuromolecular Med 13, 151-159.
36. Vassar R, Kovacs DM, Yan R, Wong PC (2009) The betasecretase enzyme BACE in health and Alzheimer's disease: Regulation, cell biology, function, and therapeutic potential. J Neurosci 29, 12787-12794.
37. Walsh DM, Selkoe DJ (2007) A beta oligomers - a decade of discovery. J Neurochem 101, 1172-1184.
38. Khlistunova I, Biernat J, Wang Y, Pickhardt M, von Bergen M, Gazova Z, Mandelkow E, Mandelkow E-M (2006) Inducible expression of Tau repeat domain in cell models of tauopathy: Aggregation is toxic to cells but can be reversed by inhibitor drugs. J Biol Chem 281, 1205-1214.
39. Israel MA, Yuan SH, Bardy C, Reyna SM, Mu Y, Herrera C, Hefferan MP, Van Gorp S, Nazor KL, Boscolo FS, Carson CT, Laurent LC, Marsala M, Gage FH, Remes AM, Koo EH, Goldstein LSB (2012) Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells. Nature 482, 216-220.
40. Querfurth HW, Laferla FM (2010) Alzheimer's disease. Clin Trials 362, 329-344.
41. Sala I, Sánchez-Saudinós MB, Molina-Porcel L, Lázaro E, Gich I, Clarimón J, Blanco-Vaca F, Blesa R, Gómez-Isla T, LleóA(2008) Homocysteine and cognitive impairment. Relation with diagnosis and neuropsychological performance. Dement Geriatr Cogn Disord 26, 506-512.
42. Petersen RC(2004) Mild cognitive impairment as a diagnostic entity. J Intern Med 256, 183-194.
43. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDAWork Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944.
44. Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, van Swieten JC, Seelaar H, Dopper EG P, Onyike CU, Hillis AE, Josephs KA, Boeve BF, Kertesz A, Seeley WW, Rankin KP, Johnson JK, Gorno-Tempini ML, Rosen H, Prioleau-Latham CE, Lee A, Kipps CM, Lillo P, Piguet O, Rohrer JD, Rossor MN, Warren JD, Fox NC, Galasko D, Salmon DP, Black SE, Mesulam M, Weintraub S, Dickerson BC, Diehl-Schmid J, Pasquier F, Deramecourt V, Lebert F, Pijnenburg Y, Chow TW, Manes F, Grafman J, Cappa SF, Freedman M, Grossman M, Miller BL (2011) Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 134, 2456-2477.
45. Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF, Ogar JM, Rohrer JD, Black S, Boeve BF, Manes F, Dronkers NF, Vandenberghe R, Rascovsky K, Patterson K, Miller BL, Knopman DS, Hodges JR, Mesulam MM, Grossman M (2011) Classification of primary progressive aphasia and its variants. Neurology 76, 1006-1014.
46. Alcolea D, Martínez-Lage P, Izagirre A, Clerigué M, Carmona-Iragui M, Alvarez RM, Fortea J, Balasa M, Morenas-Rodríguez E, Lladó A, Grau O, Blennow K, Lleó A, Molinuevo JL (2014) Feasibility of lumbar puncture in the study of cerebrospinal fluid biomarkers for Alzheimer's disease: A multicenter study in Spain. J Alzheimers Dis 39, 719-726.
47. Teunissen CE, Tumani H, Bennett JL, Berven FS, Brundin L, Comabella M, Franciotta D, Federiksen JL, Fleming JO, Furlan R, Hintzen RQ, Hughes SG, Jimenez CR, Johnson MH, Killestein J, Krasulova E, Kuhle J, Magnone M- C, Petzold A, Rajda C, Rejdak K, Schmidt HK, van Pesch V, Waubant E, Wolf C, Deisenhammer F, Giovannoni G, Hemmer B (2011) Consensus guidelines for CSF and blood biobanking for CNS biomarker studies. Mult Scler Int 2011, 246412.
48. Mattsson N, Andreasson U, Persson S, Carrillo MC, Collins S, Chalbot S, Cutler N, Dufour-Rainfray D, Fagan AM, Heegaard NH H, Robin Hsiung G- Y, Hyman B, Iqbal K, Lachno DR, Lleó A, Lewczuk P, Molinuevo JL, Parchi P, Regeniter A, Rissman R, Rosenmann H, Sancesario G, Schröder J, Shaw LM, Teunissen CE, Trojanowski JQ, Vanderstichele H, Vandijck M, Verbeek MM, Zetterberg H, Blennow K, Käser SA (2013) CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimers Dement 9, 251-261.
49. Guardia-Laguarta C, Pera M, Clarimón J, Molinuevo JL, Sánchez-Valle R, Lladó A, Coma M, Gómez-Isla T, Blesa R, Ferrer I, Lleó A (2010) Clinical, neuropathologic, and biochemical profile of the amyloid precursor protein I716F mutation. J Neuropathol Exp Neurol 69, 53-59.
50. Gabelle A, Roche S, Gény C, Bennys K, Labauge P, Tholance Y, Quadrio I, Tiers L, Gor B, Boulanghien J, Chaulet C, Vighetto A, Croisile B, Krolak-Salmon P, Perret-Liaudet A, Touchon J, Lehmann S (2011) Decreased sAβPPβ,Aβ38, and Aβ40 cerebrospinal fluid levels in frontotemporal dementia. J Alzheimers Dis 26, 553-563.
51. Holsinger RM D, Lee JS, Boyd A, Masters CL, Collins SJ (2006) CSF BACE1 activity is increased in CJD and Alzheimer disease other dementias. Neurology 67, 710-712.
52. Holsinger RM D, McLean CA, Collins SJ, Masters CL, Evin G (2004) Increased B-secretase activity in cerebrospinal fluid of Alzheimer's disease subjects. Ann Neurol 55, 898.
53. Mulder SD, van der Flier WM, Verheijen JH, Mulder C, Scheltens P, Blankenstein MA, Hack CE, VeerhuisR(2010)BACE1 activity in cerebrospinal fluid and its relation to markers ofAD pathology. J Alzheimers Dis 20, 253-260.
54. Grimmer T, Alexopoulos P, Tsolakidou A, Guo L- H, Henriksen G, Yousefi BH, Förstl H, Sorg C, Kurz A, Drzezga A, Perneczky R (2012) Cerebrospinal fluid BACE1 activity and brain amyloid load in Alzheimer's disease. Scientific World Journal 2012, 712048.
55. Holler CJ, Webb RL, Laux AL, Beckett TL, Niedowicz DM, Ahmed RR, Liu Y, Simmons CR, Dowling AL S, Spinelli A, Khurgel M, Estus S, Head E, Hersh LB, Murphy MP (2012) BACE2expression increases in human neurodegenerative disease. Am J Pathol 180, 337-350.
56. Kovacs GG, Milenkovic I, Wöhrer A, Höftberger R, Gelpi E, Haberler C, Hönigschnabl S, Reiner-Concin A, Heinzl H, Jungwirth S, Krampla W, Fischer P, Budka H (2013) Non-Alzheimer neurodegenerative pathologies and their combinations are more frequent than commonly believed in the elderly brain: A community-based autopsy series. Acta Neuropathol 126, 365-384.
57. Toledo JB, Brettschneider J, Grossman M, Arnold SE, Hu WT, Xie SX, Lee VM- Y, Shaw LM, Trojanowski JQ (2012) CSF biomarkers cutoffs: The importance of coincident neuropathological diseases. Acta Neuropathol 124, 23-35.